Provided by Tiger Trade Technology Pte. Ltd.

SBP GROUP

5.425
+0.0150.28%
Volume:26.18M
Turnover:142.07M
Market Cap:101.36B
PE:35.65
High:5.530
Open:5.490
Low:5.360
Close:5.410
52wk High:7.886
52wk Low:4.136
Shares:18.68B
HK Float Shares:18.68B
Volume Ratio:0.76
T/O Rate:0.14%
Dividend:0.12
Dividend Rate:2.21%
EPS(LYR):0.152
ROE:14.07%
ROA:7.51%
PB:2.65
PE(LYR):35.65
PS:2.57

Loading ...

Sino Biopharma Unit Grants STADA Commercialization License for Pembrolizumab Biosimilar

MT Newswires Live
·
Sep 28

SBP Group and Germany’s STADA Sign €53 Million Biosimilar Commercialisation Agreement for EU, UK and CIS

Bulletin Express
·
Sep 28

Sino Biopharmaceutical - Stada to Hold Marketing Authorizations and Sales Rights in Licensed Territory, Options for US and GCC

THOMSON REUTERS
·
Sep 28

Sino Biopharmaceutical - Enter into Strategic Biosimilars Partnership with Stada

THOMSON REUTERS
·
Sep 28

Sino Biopharmaceutical - Cttq Grants Stada Exclusive License for Pembrolizumab Biosimilar in EU, Switzerland, UK, CIS

THOMSON REUTERS
·
Sep 28

Sino Biopharmaceutical Stock Slides 1.3% in Hong Kong, Underperforms Competitors

Dow Jones
·
Sep 28

SBP GROUP Releases 2026 Interim Report Online and Opens Printed-Copy Requests for Non-Registered Shareholders

Bulletin Express
·
Sep 24

SBP Group Publishes 2026 Interim Report Online and Seeks Wider Adoption of E-Communication

Bulletin Express
·
Sep 24

Sino Biopharmaceutical Stock Slips 1.8% in Hong Kong

Dow Jones
·
Sep 24

Sino Biopharmaceutical Stock Slips 1.4% in Hong Kong, Underperforms Competitors

Dow Jones
·
Sep 22

Market Chatter: US Considers Rules Allowing American Investment in Chinese Drugs

MT Newswires Live
·
Sep 21

Hong Kong Equities Close Higher | Hang Seng Index Regains 25,000 Mark, Innovative Drug Shares Rally Broadly, SBP Group Tops Blue-Chip Gainers

Stock News
·
Sep 21

Sino Biopharmaceutical Stock Rises 8.2% in Hong Kong, Outperforms Competitors

Dow Jones
·
Sep 21

Hang Seng Index Rallies into the Close, up More Than 1%, Testing the 25,000 Level

Tiger Newspress
·
Sep 21

Hong Kong Stock Movers | SBP Group Surges Over 6% as Management Reaffirms Annual Revenue Target, with Newly Approved Innovative Drugs Set to Drive Sustained Sales Growth

Stock News
·
Sep 21

Movement Alert|SBP GROUP Rises 3.11% in Regular Trading, Management Reaffirms Double-Digit Revenue Growth Guidance with Buy Rating from Daiwa

Market Focus
·
Sep 21

Daiwa Reaffirms Buy Rating on SBP Group After Management Reiterates Double-Digit Revenue Growth Target for the Year

Deep News
·
Sep 20

Daiwa Highlights SBP Group's Reaffirmed Double-Digit Revenue Growth Target for This Year, Retains "Buy" Rating

Stock News
·
Sep 18

Movement Alert|SBP GROUP Rises 3.18% in Regular Trading, Dual NDA Acceptances and CT Tianqing Stake Increase Completion Fuel Gains

Market Focus
·
Sep 18

Hong Kong Stocks in Focus: SBP Group Jumps Nearly 3% on Double New Drug Approval Submissions

Stock News
·
Sep 16